

February 1, 2017
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Expiration of the Joint Research and Development Agreement for an Anti-cancer Drug using the TTR1 Nano-agonist Molecule

TOKYO, Japan, February 1, 2017 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, "Symbio") announced today that the term of the collaboration agreement entered into in February 2016 with Teikyo Heisei University ("the Agreement") to collaborate on the research and development of an innovative anti-cancer drug which uses the TTR1 nano-agonist molecule¹ has expired under the Agreement.

Symbio will continue to vigorously explore and evaluate opportunities for projects in collaboration with academia, industry and government, aiming for innovative therapeutic medications.

Conclusion of the Agreement with Teikyo Heisei University will have no significant impact on the Company's earnings forecast for fiscal year ending December 31, 2017.

[Contact]

Investor Relations
Tel: +81 (0)3 5472 1125